April 27, 2004; 62 (8) Special Articles
Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy
Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society
J. A. French, A. M. Kanner, J. Bautista, B. Abou-Khalil, T. Browne, C. L. Harden, W. H. Theodore, C. Bazil, J. Stern, S. C. Schachter, D. Bergen, D. Hirtz, G. D. Montouris, M. Nespeca, B. Gidal, W. J. Marks, W. R. Turk, J. H. Fischer, B. Bourgeois, A. Wilner, R. E. Faught, R. C. Sachdeo, A. Beydoun, T. A. Glauser
First published April 26, 2004, DOI: https://doi.org/10.1212/01.WNL.0000123695.22623.32
J. A. French
A. M. Kanner
J. Bautista
B. Abou-Khalil
T. Browne
C. L. Harden
W. H. Theodore
C. Bazil
J. Stern
S. C. Schachter
D. Bergen
D. Hirtz
G. D. Montouris
M. Nespeca
B. Gidal
W. J. Marks Jr.
W. R. Turk
J. H. Fischer
B. Bourgeois
A. Wilner
R. E. Faught Jr.
R. C. Sachdeo
A. Beydoun
Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy
Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society
J. A. French, A. M. Kanner, J. Bautista, B. Abou-Khalil, T. Browne, C. L. Harden, W. H. Theodore, C. Bazil, J. Stern, S. C. Schachter, D. Bergen, D. Hirtz, G. D. Montouris, M. Nespeca, B. Gidal, W. J. Marks, W. R. Turk, J. H. Fischer, B. Bourgeois, A. Wilner, R. E. Faught, R. C. Sachdeo, A. Beydoun, T. A. Glauser
Neurology Apr 2004, 62 (8) 1261-1273; DOI: 10.1212/01.WNL.0000123695.22623.32
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 62 no. 8 1261-1273
PubMed:
Print ISSN:
Online ISSN:
History:
- Received September 3, 2003
- Accepted January 24, 2004
- First Published April 26, 2004.
Copyright & Usage:
© 2004
Author Disclosures
- J. A. French, MD*,
- A. M. Kanner, MD†,
- J. Bautista, MD,
- B. Abou-Khalil, MD,
- T. Browne, MD,
- C. L. Harden, MD,
- W. H. Theodore, MD,
- C. Bazil, MD PhD,
- J. Stern, MD,
- S. C. Schachter, MD,
- D. Bergen, MD,
- D. Hirtz, MD,
- G. D. Montouris, MD,
- M. Nespeca, MD,
- B. Gidal, PharmD,
- W. J. Marks Jr., MD,
- W. R. Turk, MD,
- J. H. Fischer, MD,
- B. Bourgeois, MD,
- A. Wilner, MD,
- R. E. Faught Jr., MD,
- R. C. Sachdeo, MD,
- A. Beydoun, MD and
- T. A. Glauser, MD
- J. A. French, MD*,
- A. M. Kanner, MD†,
- J. Bautista, MD,
- B. Abou-Khalil, MD,
- T. Browne, MD,
- C. L. Harden, MD,
- W. H. Theodore, MD,
- C. Bazil, MD PhD,
- J. Stern, MD,
- S. C. Schachter, MD,
- D. Bergen, MD,
- D. Hirtz, MD,
- G. D. Montouris, MD,
- M. Nespeca, MD,
- B. Gidal, PharmD,
- W. J. Marks Jr., MD,
- W. R. Turk, MD,
- J. H. Fischer, MD,
- B. Bourgeois, MD,
- A. Wilner, MD,
- R. E. Faught Jr., MD,
- R. C. Sachdeo, MD,
- A. Beydoun, MD and
- T. A. Glauser, MD
- From the University of Pennsylvania (Dr. French), Philadelphia; Department of Neurological Sciences (Drs. Kanner and Bergen), Rush Medical College, Chicago, IL; The Cleveland Clinic Foundation (Dr. Bautista), OH; Vanderbilt University Medical Center (Dr. Abou-Khalil), Nashville, TN; Boston University Medical Center (Drs. Browne and Montouris), MA; Weill Medical College of Cornell University (Dr. Harden), New York, NY; National Institutes of Neurological Disorders and Stroke (Drs. Theodore and Hirtz), National Institutes of Health, Bethesda, MD; Columbia Presbyterian Medical Center (Dr. Bazil), New York, NY; Beth Israel Deaconess Medical Center and Harvard Medical School (Drs. Stern and Schachter), Boston, MA; Children’s Hospital San Diego (Dr. Nespeca), CA; School of Pharmacy and Department of Neurology (Dr. Gidal), University of Wisconsin Hospital and Clinics, Madison; University of California San Francisco Epilepsy Center (Dr. Marks), CA; Nemours Children’s Clinic Div. of Neurology (Dr. Turk), Jacksonville, FL; University of Illinois College of Pharmacy (Dr. Fischer), Dept. of Pharmacy Practice and Neurology, Colleges of Pharmacy and Medicine, Chicago; Department of Neurology (Dr. Bourgeois), Children’s Hospital, Boston, MA; Private practice (Dr. Wilner), Providence, RI; Department of Neurology (Dr. Faught), University of Alabama School of Medicine, Birmingham; Dept. of Neurology (Dr. Sachdeo), University of Medicine and Dentistry of New Jersey, New Brunswick; Dept. of Neurology (Dr. Beydoun), University of Michigan, Ann Arbor; and Dept. of Neurology (Dr. Glauser), Children’s Hospital Medical Center, Cincinnati, OH.
- Address correspondence and reprint requests to TTA and QSS subcommittees, American Academy of Neurology, 1080 Montreal Ave., St. Paul, MN 55116
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- Reply to Panayiotopoulos et al
- Jacqueline French, TTA and QSS subcommittees, American Academy of Neurology, 1080 Montreal Ave., St. Paul, MN 55166kathy_pieper@urmc.rochester.edu
Submitted September 15, 2004 - Efficacy and tolerability of the new antiepileptic drugs: Commentary on the practice parameters
- C.P. Panayiotopoulos, Dept. of Clinical Neurophysiology and Epilepsies, St. Thomas' Hospital, London SE1 7EHtom.panayiotopoulos@gstt.sthames.nhs.uk
- Selim R. Benbadis, Athanasios Covanis, Olivier Dulac, John S. Duncan, Orvar Eeg-Olofsson, Colin D. Ferrie, Richard A. Grunewald, Dorothee G.A. Kasteleijn-Nolst Trenite, Michael Koutroumanidis, Zarko Martinovic, Richard W. Newton, Alasdair P. Parker,
Submitted September 15, 2004
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement